comprehensive -WSS

comprehensive

author：leisure time 2025-09-03 09:20:39 - browse：34225

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Elizabeth Holmes banned from government health programs

WSS

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Medicare Advantage today, explained in one chart

Biotech venture capitalists face new demands from investors

Readout Newsletter: Merck, J&J, and long Covid

Parkinson’s finding may lead to tests and, someday, treatments

Do more moles mean more problems? Not so, says new study

hotspot

comprehensive

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Heat waves linked to early deliveries, preterm births in new study

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Novavax promises a turnaround & Lilly roils the obesity market

Do more moles mean more problems? Not so, says new study

Guidelines to prevent youth baseball injuries need more muscle

Latest bird flu infection made farmworker sicker than earlier cases

Hepatitis C has a cure — but many Americans still lack access to it

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

explore

Dark money group runs ads on China biotech bill

Lab trade group sues FDA to halt regulation of lab

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Humana cuts profit projections as Medicare Advantage costs soar

Childbirth

Wikipedia

Wikipedia

Wikipedia

knowledge